32.13
0.52 (1.65%)
| Previous Close | 31.61 |
| Open | 31.14 |
| Volume | 621,567 |
| Avg. Volume (3M) | 896,717 |
| Market Cap | 1,910,783,360 |
| Price / Book | 5.03 |
| 52 Weeks Range | |
| Earnings Date | 13 Aug 2026 |
| Diluted EPS (TTM) | -1.63 |
| Total Debt/Equity (MRQ) | 1.89% |
| Current Ratio (MRQ) | 22.78 |
| Operating Cash Flow (TTM) | -73.20 M |
| Levered Free Cash Flow (TTM) | -37.79 M |
| Return on Assets (TTM) | -19.00% |
| Return on Equity (TTM) | -27.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Tyra Biosciences, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.67 |
|
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company’s in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.69% |
| % Held by Institutions | 108.46% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Alta Partners Management Company, L.P. | 31 Mar 2026 | 3,823,425 |
| Bvf Inc/Il | 31 Mar 2026 | 1,976,196 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |